---
title: "OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial"
date: 2025-09-02T22:36:26+08:00
categories: ["tech"]
tags: ["Health", "allergies", "COVID-19", "nasal spray", "respiratory infections", "robert f kennedy jr"]
summary: "The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted."
source_url: "https://arstechnica.com/health/2025/09/otc-nasal-spray-seemed-to-cut-covid-infections-by-67-in-mid-sized-trial/"
---

The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.

---

*来源: [原文链接](https://arstechnica.com/health/2025/09/otc-nasal-spray-seemed-to-cut-covid-infections-by-67-in-mid-sized-trial/)*
